Clinical trials: Dysmenorrhea Primary
Dysmenorrhea, Headache, Migraine
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
- Conditions
- Dysmenorrhea, Headache, Migraine, Fatigue, Nausea
- Trial name
- NCT04091789
- Testing
- Pure Femme Tablets
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pure Green
Primary Dysmenorrhea
Study to Evaluate the Efficacy and Safety of Dexketoprofen / Butylscopolamine vs Dexketoprofen in Treatment of Primary Dysmenorrhea
This study seeks to evaluate the efficacy and safety of the fixed dose combination of dexketoprofen/butylscopolamine compared to dexketoprofen for the treatment of primary dysmenorrhea in 130 mexican women.
- Trial name
- NCT07901894
- Testing
- Dexketoprofen / Butylscopolamine in fixed dose combination tablet. (Laboratorios Silanes S.A. de C.V.), Dexketoprofen (Stadium®, Menarini Manufacturing Logistics and Services S.R.L. Conditioned by Grimann, S.A. de C.V. Distributed by: Sanfer Laboratories S.A. de C.V.)
- Where
- 4 sites in Mexico
- Volunteers
- 130 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Primary Dysmenorrhea
Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea
Dysmenorrhea is characterized as excruciating menstrual cramps of uterine origin and is one of the most prevalent gynecological illnesses.
- Trial name
- NCT06317064
- Testing
- Ibuprofen and Aprepitant
- Where
- Pakistan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lahore Medical Research Center, LLP
Primary Dysmenorrhea
VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept
The purpose of the study is to investigate how effective VA111913 is at preventing menstrual pain in women with primary dysmenorrhoea.
- Trial name
- NCT00963053
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 146 people
- Sponsor
- Vantia Ltd
Dysmenorrhea
Drotaverine in Dysmenorrhoea Treatment
The aim of the study is to show that the combination of drotaverine 80mg and ibuprofen 400 mg is more effective and as well-tolerated as ibuprofen 400 mg or drotaverine 80 mg administered alone, in the treatment of primary and…
- Trial name
- NCT00292747
- Testing
- Drotaverine, Ibuprofen
- Where
- Hungary
- Volunteers
- 480 people
- Sponsor
- Sanofi
Dysmenorrhea
Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea
The purpose of this study is to determine a safe and effective dose range for intravenous administration (infusion) of PDC31 by determining the maximum tolerated dose of PDC31 in patients with primary dysmenorrhea.
- Trial name
- NCT01250587
- Testing
- PDC31
- Where
- 4 sites in Austria, Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- PDC Biotech GmbH
Migraine Disorders
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea
This study was designed to determine efficacy of TREXIMA compared to placebo for the treatment of a menstrual migraine.
- Trial name
- NCT00329459
- Testing
- sumatriptan succinate/naproxen sodium
- Where
- 34 sites in United States
- Volunteers
- 320 people
- Sponsor
- GlaxoSmithKline
Dysmenorrhea
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in the Treatment of Women With Primary Dysmenorrhea (MK-8342B-060)
The purpose of this study was to evaluate the efficacy of the etonogestrel (ENG) + 17β-estradiol (E2) (MK-8342B) vaginal ring compared to placebo vaginal ring in the treatment of dysmenorrhea at Treatment Cycle 2.
- Trial name
- NCT02668822
- Testing
- ENG 125 μg + E2 300 μg vaginal ring (MK-8342B), Ibuprofen
- Volunteers
- 18 people
- Sponsor
- Organon and Co
Dysmenorrhea
Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)
The purpose of this study is to determine whether lidocaine vaginal gel is safe and effective for preventing or reducing the severity of dysmenorrhea (painful menstrual periods) compared to placebo (inactive gel).
- Trial name
- Lidocaine 04 (NCT00651313)
- Testing
- Lidocaine
- Where
- 4 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Juniper Pharmaceuticals, Inc.
Dysmenorrhea
Assessment of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea
The investigators propose that the sustained administration of a vaginal ring would have a better response with respect to pain and a better safety profile than the oral administration of a non-steroidal anti-inflammatory drug.
- Trial name
- NCT02255045
- Testing
- Meloxicam, Diclofenac Potassium
- Where
- Chile
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Laboratorios Andromaco S.A.
Primary Dysmenorrhea, Menstural Cramps
Efficacy of CL25216 on Hormonal Balance and Menstrual Health in Women With Primary Dysmenorrhea.
This study is to evaluate the effects of CL25216 on hormonal balance and menstrual health in women with primary dysmenorrhea. Enrolled subjects will receive either CL25216 - 250 mg/day or placebo.
- Trial name
- PD (NCT07529561)
- Testing
- CL25216
- Where
- India
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- ApexCPG LLC
Dysmenorrhea
The Effectiveness and Safety of LIVIA® Transcutaneous Electrical Nerve Stimulation (TENS) in Women Suffering From Primary Dysmenorrhea.
This is a randomized, controlled, multi-center, single-arm, crossover, double-blind clinical study assessing the Livia Transcutaneous Electrical Nerve Stimulation (TENS) in women suffering from dysmenorrhea.
- Trial name
- NCT03064945
- Testing
- Livia
- Where
- Israel
- Volunteers
- 63 people
- Sponsor
- iPulse Medical Ltd. (Livia)
Dysmenorrhea Primary
A Study of Diclofenac Gel in Women With Primary Dysmenorrhea
The goal of this clinical trial is to compare 1% and 3% diclofenac gel (DARE-PDM1) to placebo in women with symptomatic primary dysmenorrhea.
- Trial name
- DARE-PDM1 (NCT05752526)
- Testing
- Diclofenac 1%, Diclofenac 3%
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Daré Bioscience, Inc.